Published on 21 Jun 2016
Summit
Therapeutics (LON:SUMM NASDAQ:SMMT) Senior Director Richard Pye tells
Proactive Investors that their treatment Ridinilazole can trump current
treatments for Clostridium Difficile Infection (CDI). "We think this
can really alter the treatment paradigm" he says.
Pye says the current treatments for CDI are actually quite good at killing the infection but they then cause more damage to the patient's microbiome - bacteria in the gut that fights infections. "We are able to both treat the initial infection and allow the patient to have their microbiome providing natural protection against developing recurrent disease" he says.
www.summitplc.com
http://www.4-traders.com/SUMMIT-THERAPEUTICS-PLC-18044789/
http://www.4-traders.com/SUMMIT-THERAPEUTICS-PLC-21452860/
www.proactiveinvestors.com/LON:SUMM/Summit-Therapeutics-PLC/
Pye says the current treatments for CDI are actually quite good at killing the infection but they then cause more damage to the patient's microbiome - bacteria in the gut that fights infections. "We are able to both treat the initial infection and allow the patient to have their microbiome providing natural protection against developing recurrent disease" he says.
www.summitplc.com
http://www.4-traders.com/SUMMIT-THERAPEUTICS-PLC-18044789/
http://www.4-traders.com/SUMMIT-THERAPEUTICS-PLC-21452860/
www.proactiveinvestors.com/LON:SUMM/Summit-Therapeutics-PLC/
No comments:
Post a Comment